Portfolio Strategy Report: Three Portfolio Frameworks for Global Pharma Investment

Income & Stability  |  Balanced Growth  |  High Conviction

Prepared by richstorm.co •  April 2026

Key Takeaways

▸  All three portfolios are designed for positive long-term returns. No negative yield exists; the difference across profiles lies in how returns are delivered — income vs. capital appreciation.

▸  The four BUY-rated companies (AstraZeneca, Merck, Roche, Eli Lilly) drive returns in all growth-oriented portfolios. HOLD-rated companies provide defensive income and stability.

▸  Patent cliff timing is the primary portfolio management variable in pharma. The report stagger across 2026 (Novartis/Pfizer), 2028 (Merck/BMS), and remote (Lilly) provides natural diversification.

▸  AstraZeneca, Novartis, and Roche are non-US companies (not S&P 500 eligible) that trade as ADRs. Their inclusion adds geographic and therapeutic diversification that US-only portfolios cannot replicate.

PORTFOLIO SUMMARY AT A GLANCE

Portfolio 1: Income & Stability 

The Income & Stability portfolio is constructed for investors who prioritise reliable dividend income, capital preservation, and low volatility. It allocates primarily to HOLD-rated companies with strong cash flows, long dividend track records, and visible earnings — while including two BUY-rated names (Merck and Roche) for modest growth exposure and diversification.

ALLOCATION

TOTAL RETURN PROJECTION

PORTFOLIO RATIONALE & MANAGEMENT NOTES 

Dividend income rationale: The 3.8% blended yield is among the highest achievable in large-cap pharma without taking on excessive concentration risk. Pfizer (6.4%) and BMS (4.2%) contribute the heaviest income load, with Novartis (3.2%) and Roche (3.1%) providing international diversification of the income stream.

Why Eli Lilly and AstraZeneca are excluded: Both companies yield below 2% and reinvest aggressively into R&D and manufacturing rather than dividends. Their inclusion would dilute the blended yield below 3% without commensurate income benefit. They are better suited to growth-oriented profiles.

Portfolio management trigger: If Pfizer cuts its dividend — signalled by a payout ratio breach or management guidance change — reduce Pfizer to 12% and reallocate evenly to Merck and Roche. A Pfizer dividend cut would also likely compress the stock price by 15-20%, making the rebalance timely. 

Geographic mix: 90% US-listed (PFE, JNJ, BMY, MRK) and 10% Swiss ADR (RHHBY). This provides US tax simplicity for most investors while capturing Roche's 39-year dividend track record and diagnostics moat.

Portfolio 2: Balanced Growth

The Balanced Growth portfolio is designed for mid-career investors with a 5-10 year horizon who seek capital appreciation as the primary objective while maintaining a modest income floor. The four BUY-rated companies comprise 72% of the portfolio, providing meaningful exposure to the best fundamental stories in the sector. Three HOLD-rated names provide defensive ballast and reduce overall portfolio volatility.

ALLOCATION

TOTAL RETURN PROJECTION

PORTFOLIO RATIONALE & MANAGEMENT NOTES 

Why four BUYs at 72% weight: Each BUY serves a different function within the portfolio. Eli Lilly delivers momentum-driven growth from the GLP-1 secular wave. AstraZeneca delivers pipeline-compounding quality growth. Merck delivers value-driven recovery as the market misprices the 2028 Keytruda cliff. Roche delivers structural moat growth via its unique pharma-diagnostics integration. Together, they cover four distinct investment styles within a single sector.

BMS at 5% (not zero): A small position in BMS captures the upside from the 2026 milvexian and iberdomide catalysts without taking material risk. If both succeed, BMS could re-rate 30-40% upward in 2026 — a 5% position would add ~1.5-2% to total portfolio return. If both fail, the 5% position limits the damage.

Rebalancing rule: If Eli Lilly exceeds 30% of portfolio value due to price appreciation (likely given 40%+ EPS growth), trim back to 22% and redeploy into Merck or Roche — both of which would still be materially undervalued at that point in time. 

Geographic mix: 60% US-listed (LLY, MRK, JNJ, BMY) and 40% international (AZN as UK/Swedish ADR, RHHBY as Swiss ADR, NVS as Swiss ADR). This geographic balance is intentional — US IRA/drug pricing headwinds disproportionately affect US-domiciled pharma; European companies face different but generally lower regulatory pricing pressure.

Portfolio 3: High Conviction Growth 

The High Conviction Growth portfolio concentrates exclusively on the four BUY-rated companies, eliminating all HOLD-rated holdings to maximise exposure to companies with the strongest fundamental growth trajectories. This is a pure-growth, long-duration portfolio designed for investors who are comfortable with higher short-term volatility in exchange for superior long-term compounding. The 1.6% blended yield is not the objective — the target is 17-27% total annual return over a 7-15 year horizon.

ALLOCATION

TOTAL RETURN PROJECTION

PORTFOLIO RATIONALE & MANAGEMENT NOTES 

Eli Lilly at 35% — the maximum advisable concentration: Lilly is the highest-quality growth story in pharma, but GLP-1 concentration risk (>50% of revenue tied to Mounjaro/Zepbound) justifies capping the individual position. A 35% portfolio weight means that if an adverse GLP-1 event causes a 30% LLY drawdown, the portfolio impact is a manageable ~10.5% total decline — recoverable within a typical annual appreciation cycle.

AstraZeneca at 30%: AZN is arguably the safest high-growth option in the cohort — diversified across oncology, cardiovascular, immunology, and the emerging GLP-1 space, with the cleanest balance sheet of the four (net debt/EBITDA just 1.2x). Its 100+ Phase 3 pipeline makes any single trial failure non-catastrophic to the overall investment thesis, unlike BMS where two drugs represent the entire recovery story.

Entry point strategy for this portfolio: Eli Lilly frequently experiences 15-20% drawdowns on competitive GLP-1 news (Novo Nordisk trial results, oral GLP-1 competitor data). These drawdowns are historically among the best entry points in large-cap pharma. Use limit orders 15% below current price to add to LLY positions on weakness. 

Why HOLD-rated companies are excluded entirely: Pfizer, J&J, Novartis, and BMS all have identifiable near-term headwinds (patent cliffs, litigation, trough earnings) that will likely constrain price appreciation over 1-3 years. For a 7-15 year investor, allocating capital to these companies means accepting lower compounding than the BUYs would deliver — a drag on long-run portfolio value. HOLD-rated companies are appropriate for income-seeking investors, not long-duration growth compounders.

Holding Period Framework

The appropriate holding period for each pharma stock is determined by three factors: (1) the timing of its most significant patent cliff, (2) the maturity of its pipeline replacement engine, and (3) the presence of a binary catalyst that could materially re-rate the stock in either direction. The table below provides minimum and optimal holding recommendations for each company as of April 2026.

The minimum holding period recommendation reflects the time needed for each company's primary catalyst to materialise. Selling before the minimum hold risks crystallising temporary weakness from patent cliffs, litigation uncertainty, or near-term guidance misses — all of which are already reflected in current valuations for HOLD-rated companies.

Portfolio Risk Dimension Matrix 

The risk matrix below assesses each company across three critical dimensions specific to pharmaceutical investing: patent cliff risk (the severity and imminence of loss of exclusivity events), pipeline execution risk (the probability that clinical programs fail to deliver expected revenues), and FX/geopolitical risk (currency translation exposure for international companies and geographic concentration in politically sensitive markets such as China).

Portfolio-level risk insights:

The Income & Stability portfolio (PFE, JNJ, NVS, BMY, MRK, RHHBY) carries elevated patent cliff risk in aggregate but low geopolitical risk — appropriate for investors seeking predictable income without international complexity.

The Balanced Growth portfolio (LLY, AZN, MRK, RHHBY, JNJ, NVS, BMY) balances cliff risk (spread across 2026 and 2028) with moderate FX exposure from AZN and RHHBY — suitable for investors comfortable with some international currency variability.

The High Conviction portfolio (LLY, AZN, MRK, RHHBY) has the lowest patent cliff risk of the three (Lilly: remote; AZN: medium; Merck: 2028; Roche: medium) but the highest FX risk from AZN and RHHBY combined representing 45% of the portfolio.

Critical Catalyst Calendar 2026-2028 

The following catalysts represent the key decision points for portfolio management through 2028. Critical-impact events are existential for the investment thesis of the relevant company and should trigger a full portfolio review if they materialise negatively. High-impact events will likely cause 15-30% stock moves and warrant reassessment of position sizing.

Three Core Portfolio Principles

1. Stagger patent cliff exposure across time 

Never concentrate more than 30% of portfolio value in companies whose primary patent cliffs arrive within the same 12-month window. The current natural stagger in this cohort — Pfizer/Novartis cliffs active in 2026, BMS/Merck cliffs in 2028, and Lilly/AstraZeneca/Roche cliffs remote or manageable — provides inherent cushion. One set of patent losses does not amplify another when they are separated by 18-24 months. This stagger is one of the structural advantages of holding a diversified pharma basket rather than concentrating in a single company.

2. Use GLP-1 volatility as a systematic entry opportunity 

Eli Lilly's stock is highly sensitive to competitive GLP-1 news — a Novo Nordisk trial result, a competitor's Phase 2 weight loss announcement, or a PBM formulary change can trigger 15-20% drawdowns within days, even when Lilly's own fundamentals are unchanged. These drawdowns have historically been among the best entry points in large-cap pharma. The 45% revenue growth in 2025 and 25%+ guidance for 2026 provide a strong fundamental floor. Setting limit orders 15-20% below the current price ensures disciplined accumulation during fear-driven selling.

3. Balance geographic exposure across US, UK-European, and Swiss pharma 

A US-only pharma portfolio (Pfizer, J&J, Lilly, Merck, BMS) concentrates IRA drug pricing risk, misses two decades of Swiss capital discipline at Roche and Novartis, and forgoes AstraZeneca's uniquely deep pipeline. The target geographic mix for optimal diversification is 60-70% US-listed (S&P 500 eligible), 15-20% Swiss ADR (Roche, Novartis), and 10-15% UK/European (AstraZeneca). This configuration ensures that US regulatory pricing headwinds do not disproportionately affect the entire portfolio simultaneously.

If you found this analysis useful, RichStorm publishes independent pharma investment research grounded in science. Subscribe free to receive new insights directly in your inbox. [Subscribe here]

Prepared by RichStorm LLC | April 2026 | For informational purposes only. Not investment advice. All information based on publicly available sources. Past performance is not indicative of future results. Readers should consult a qualified financial adviser before making investment decisions.